HOME >> BIOLOGY >> NEWS
'Injectable' tissue implant could repair ravages of breast cancer surgery

Clemson University researchers have developed an injectable tissue implant that could be used to repair damage caused by breast cancer surgeries.

The work is headed by Karen Burg, a Clemson bioengineer just named to MIT's Technology Review 100 top innovators list. Burg's work with injectable transplants could one day provide breast-cancer patients a viable reconstructive surgical solution for damage left by lumpectomies and other invasive procedures. The implant, made of donor cells grown onto tiny beads, could reduce scarring, help restore the breast's natural shape and promote quicker surgical recoveries, said Burg, a Clemson alumna recruited to Clemson four years ago to help develop its tissue engineering program.

"It's thrilling to be a part of a project that could have such a profound impact on women's lives," said Burg, an associate bioengineering professor.

The research calls for cells to be grown on a scaffolding of tiny beads, then mixed with a gel and injected into the human body. Gel and beads are absorbed, leaving only the cells, which grow to fill the damaged area.

If the testing goes well, the injectable transplant technology could be ready for use in humans within 10 to 15 years. Burg's work could provide the first permanent biologically based reconstructive solution for breast-cancer survivors. The need is immense: An estimated 74,000-plus American women undergo breast reconstructions each year to repair damage from invasive procedures such as lumpectomies and mastectomies.

Burg's research also has potential in bone reconstruction and spinal disc repair. Treatment of patients with tissue and organ failure, which includes bone, accounts for approximately 50 percent of a total health care cost of $400 billion in the United States.

Burg's research has drawn wide attention from the scientific community.

In September, Technology Review, MIT's Magazine of Innovation, named Burg to its 2003
'"/>

Contact: Sandy Dees
sdeesba@clemson.edu
864-655-4193
Clemson University
1-Oct-2003


Page: 1 2

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. Tufts University establishes $4 million dollar tissue engineering resource center
3. Single isolated mouse skin cell can generate into variety of epidermal tissues
4. Patented process preserves transplant tissues/organs
5. U-M scientists find common virus in human prostate tissue
6. Cell study leap forward for tissue engineering, diseases
7. Growing replacement teeth and dental tissues
8. Jefferson researchers develop microchip to track genetic signature of cancer and normal tissue
9. DCI donor services begins distribution of tissue implants
10. Embryonic stem cell - based tissue engineering may help repair damaged heart muscle
11. Researchers use novel technology to extract RNA from archive formalin-fixed paraffin-embedded tissue

Post Your Comments:
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: